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Abstract
Biofilm is a complex matrix consisting of extracellular polysaccharides, DNA, 
and proteins that protect bacteria from a variety of physical, chemical, and biologi-
cal stresses allowing them to survive in hostile environments. Biofilm formation 
requires three different stages: cell attachment to a solid substrate, adhesion, and 
growth. The inhibition of one of these steps by small molecules, such as antimicro-
bial peptides, or their action on specific targets will leave pathogens armless against 
classical antibiotics. Any drug impairing crucial processes for bacterial life will 
inevitably lead to the development of drug-resistant strains, whereas the inhibition 
of biofilm formation might prevent the onset of bacterial resistance. In this sec-
tion, we will focus on proteins involved in biofilm formation as useful targets for 
the development of new drugs that can effectively and specifically impair biofilm 
formation with slight effects on cell survival, thus avoiding the generation of drug-
resistant strains.
Keywords: bacterial biofilms, biofilm inhibition, antimicrobial peptides,  
protein target, mechanism of action
1. Introduction
Microorganisms have the extraordinary ability to live in almost all environments 
and to protect themselves from external agents through sophisticated survival 
mechanisms. Bacteria can be found in planktonic form or in specific conditions, as 
sessile aggregates on both biotic and abiotic surfaces originating complex structures 
known as biofilm.
Biofilms are an ensemble of microbial cells irreversibly associated with a surface 
and enclosed in an essentially self-produced matrix. The biofilm matrix consists of 
polysaccharides, proteins, and DNA and constitutes a stubborn source that protects 
bacteria from a variety of physical, chemical, and biological stresses. One of its 
characteristics is the capability to impair antimicrobial molecules to spread through 
the polymer matrix or the ability of the matrix material to inactivate antibacterial 
molecules. Today, the increase and spread of antibiotic resistance among micro-
organisms (bacteria, fungi, viruses, and parasites) represent one of the greatest 
emergencies for human health worldwide [1]. Based on these characteristics, 
biofilm plays crucial roles in humans and nonhuman infections and represents the 
most important adaptive mechanism closely related to pathogenicity.
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An antibiofilm agent must display several specific characteristics to target the 
biofilm lifestyle. First, due to the temporal biofilm heterogeneity, it must show a 
rapid killing ability to face a changing entity and to target cells before their entry 
into the biofilm community; it must be able to act in different environmental niches 
and to target different growth rate cells. The cells located in the periphery of biofilm 
are directly in contact with nutrients and oxygen, while those placed deepest in 
the biofilm layers may undergo lack of nutrients, anoxia, and acidic conditions. In 
this way, a metabolic and spatial heterogeneity is generated including both rapidly 
and slowly growing cells. In particular, due to environmental conditions, inside 
the biofilm, it is possible to find the so-called persister, dormant, quiescent cells 
characterized by a low rate of cell division that are believed to play an essential 
role in the biofilm resistance to antibiotics [2]. Other important characteristics for 
a good antimicrobial candidate are the ability to interfere with the production of 
the extracellular matrix and the possibility to penetrate the biofilm architecture. 
This matrix consists for 90% of EPS, whose principal components are proteins, 
polysaccharides, lipids, and extracellular DNA, and it is involved into the biofilm 
architecture maintenance. An antibiofilm agent should also be able to interfere with 
bacterial cell communication machinery.
This chapter aims to investigate and clarify in detail the inhibition of biofilm 
formation by different approaches.
Other additional aspects to consider the identification of potential antimicrobial 
agents are the ability to recruit immune cells and/or modulate the host immune 
response and the synergy with other conventional and unconventional antimicro-
bial compounds [3, 4].
Biofilms are very dynamic and spatially heterogeneous structures originating 
gradients of oxygen, nutrients, and pH, and their formation occurs through three 
phases: adhesion, maturation, and dispersal phase as described earlier.
2. Small molecules capable to inhibit biofilm formation
The inhibition or prevention of biofilm formation has been a subject of study 
for a long time. The first important action against biofilm formation is to prevent 
bacterial adhesion to surfaces and host tissues to reduce infection [5]. Preventing 
bacterial adhesion is an attractive target [6] for hampering bacterial infection, 
and several different strategies have been proposed including hindering cellular 
receptors from recognizing adhesion surfaces or inhibiting the process of bacterial 
adhesion. Blocking the primary colonizers can prevent initial biofilm coloniza-
tion and the subsequent infection produced by planktonic cells released from the 
biofilm itself.
The adhesion process consists of various distinct steps. In the first step, bacterial 
cell establishes reversible adhesion interactions on host surfaces [7], while in the 
second step, a stronger type of adhesion is carried out, which involves specific mol-
ecules that bind in a complementary manner [5]. In particular, in Gram-negative 
bacteria, adhesion is mediated by special proteins known as adhesins associated 
with cell surface structures such as fimbriae or pili [8, 9]. Initial adhesion is then 
followed by a complex colonization process that offers a number of advantages to 
bacteria, including increased protection against dislocation by hydrokinetic forces 
from fluid surfaces or better access to nutrients released by the host cells [10]. 
Finally, in these favorable conditions, the development of the elaborate biofilm 
structures can take place.
For a long time, the first strategies used to inhibit the adhesion process were 
focused on the use of adhesin analogues that bind to the receptor and competitively 
3Inhibition of Bacterial Biofilm Formation
DOI: http://dx.doi.org/10.5772/intechopen.90614
block bacterial adhesion [5]. However, this strategy resulted unpractical because 
adhesin proteins are not readily available, and they become toxic at the relatively 
high concentrations that had to be used. An attempt to overcome this problem 
consisted in the design and use of synthetic peptides mimicking the sequence of cell 
surface adhesins. For example, the small peptide p1025 inhibits Streptococcus mutans 
binding to dental surfaces [11]. Analogously, a fragment of the fimbrillin adhesin 
was found to inhibit the adhesion of Porphyromonas gingivalis to hydroxyapatite 
[12]. However, this approach showed several drawbacks as different adhesins 
usually mediate the adhesion process and the expression of carbohydrates or cell 
surface ligands may vary depending on environmental conditions, originating a 
large number of variables and making this approach more difficult and not very 
applicable.
A novel and interesting approach to inhibit bacterial adhesion consists in the 
use of cell coatings with antimicrobial peptides that alter the chemical properties 
of the surface [13, 14], thus interfering with bacterial adhesion and preventing 
surface binding. Although “passive,” this method is rather attractive and may serve 
as a novel approach to address the biofilm problem on artificial medical devices. 
However, limited successes have been achieved so far due to attachment variability 
among different bacterial strains. Recently, many active polymeric coatings were 
designed to bind the surface and release a variety of antimicrobial molecules such 
as antibiotics, bacteriocins, and metal ions [15–18]. A significant reduction in 
biofilm formation of Staphylococcus epidermidis on hydrogel-coated and serum/
hydrogel-coated silicone catheters was observed following the release of bacteri-
ophagic factors from the polymer with and without supplemental divalent cations 
[19]. Similarly, treatment of piperacillin-tazobactam coated tympanostomy tubes 
reduces biofilm infection of ciprofloxacin-resistant Pseudomonas aeruginosa (CRPA) 
[20]. The negative aspect of this approach might be the continuous release of high 
concentration of antimicrobials in a short time by the active polymer often higher 
than the MIC values without a specific target. However, target release polymer 
can be foreseen as the new era of biofilm treatments in industrial food safety and 
packaging [21].
Recently, great attention was paid to a different approach addressed to killing 
planktonic cells for prevention and treatment of biofilms. The new catheter lock 
solution C/MB/P (citrate, methylene blue, and parabens) was able to act against 
planktonic and sessile bacteria within a biofilm preventing bacterial colonization 
of hemodialysis catheters [22]. Killing planktonic cells might represent a good 
approach, but this strategy cannot be carried out on long term because any drug 
targeting crucial processes for bacterial life will unavoidably lead to the develop-
ment of resistant strains.
An effective and positive control of biofilm formation might be obtained by 
interfering with specific cellular process crucial for biofilm formation. Biofilm 
formation is often associated with the phenomenon of quorum sensing (QS), 
in which bacterial cells communicate with each other by small diffusible signal 
molecules [23]. Moreover, bacterial gene expression has to be synchronized to 
form biofilms, and to achieve this goal, the quorum-sensing (QS) mechanism is 
used by bacteria, producing and responding to a several intra and intercellular 
signals called autoinducers [24]. At low-cell densities, the autoinducer is present 
in the extracellular media in a small amount that is too dilute to be detected. When 
the cell density increases, the autoinducer concentration reaches a threshold, and  
the autoinducer-receptor complex (the regulatory protein) acts to induce or 
repress the expression of target genes. The QS controls some physiological pro-
cesses such as secretion of virulence factors, biofilm formation, and antibiotic 
resistance in several bacterial species [25, 26]. Investigation and elucidation of 
Bacterial Biofilms
4
the molecular mechanisms underlying the QS effects on biofilms including the 
production of virulence factors may help to control bacterial infection. More than 
70 species of Gram-negative bacteria communicate and control their population 
density and mobility via N-acyl homoserine lactones (AHLs) mediated QS and 
represented one of the primary scaffolds studied for the design of potential biofilm 
inhibitors [27]. N-butanoylhomoserine lactone 1 (C4-AHL, for the rhl system) 
and 3-oxo-C12-AHL 5 (for the las system) are among the most important AHLs 
involved in QS (REF Small molecule control of bacterial biofilms). In P. aerugi-
nosa, one of the most important bacteria involved in human infections, different 
antibiofilm molecules focused on AHL analogues were designed to develop new 
strategies to impair biofilm formation. The Blackwell et al. identified, designed, 
and synthesized several different AHLs capable to significantly reduce biofilm 
formation and virulence factor production in P. aeruginosa [28, 29].
A different approach consisted in the use of the synthetic halogenated furanone 
produced by secondary metabolism of the Australian macroalga Delisea pulchra, 
which is able to penetrate the biofilm matrix and to alter its architecture in flow 
chambers [30, 31]. Furthermore, T315, an integrin-linked kinase inhibitor previ-
ously identified as a potential therapeutic agent against chronic lymphocytic leu-
kemia [32], was shown to selectively inhibit biofilm formation in both Salmonella 
typhi and Salmonella Typhimurium at early stages of biofilm development without 
affecting bacterial viability. T315 was also demonstrated to reduce biofilm forma-
tion in Acinetobacter baumannii but had no effect on P. aeruginosa suggesting a 
bacterial specificity [33].
3. Biofilm inhibition by antimicrobial peptides
Antimicrobial peptides (AMPs) are small molecules (10–100 amino acids) 
widespread in nature that play an essential role in the innate immunity. Recently, 
much attention has been paid to AMPs as they exert a broad spectrum of action, 
exploiting different activities as antibacterial, antifungal, antiparasites, antican-
cer, and antibiofilm factors [34]. This paragraph will focus on the ability of some 
antimicrobial peptides to inhibit biofilm formation.
The use of antimicrobial peptides to impair biofilm formation is attracting great 
interest, and many peptides have already been tested on different bacterial biofilms. 
In particular, the molecular mechanism of biofilm inhibition by AMPs is very much 
under investigation. The AMPs tested on biofilms so far derive from different 
natural sources, such as humans, mammals, bacteria, plants, and amphibians, but 
many synthetic peptides have also been studied. For example, it was demonstrated 
that the human cathelicidin LL-37 and indolicidin peptides could prevent biofilm 
formation of P. aeruginosa by downregulating the transcription of Las and Rhl, two 
quorum-sensing systems [35]. Moreover, AMPs could inhibit biofilm formation by 
increasing twitching motility in P. aeruginosa through the stimulation of the expres-
sion of genes needed for type IV pilli biosynthesis and function. Type IV pilli has 
the main function to increase bacteria movement on surfaces, which could facilitate 
cell removal [35]. The synthetic antimicrobial peptide meta-phenylene ethynylene 
(mPE), based on magainin, was active against biofilms of Streptococcus mutans, both 
as an intracellular antibiotic by binding to DNA and as a membrane-active molecule 
inhibiting lipopolysaccharides (LPSs), similar to magainin action [36].
In addition, the LL-37 peptide can also inhibit initial biofilm attachment. 
In Pseudomonas aeruginosa, this peptide downregulates the expression of genes 
associated with the assembly of flagella involved in the process of initial adherence 
[37]. Antiadhesion could be one of the major AMPs antibiofilm properties leading 
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to their potential use as an effective pretreatment strategy. For example, the nisin 
peptide, which interferes with cell wall synthesis and is capable to form membrane 
pores, delays biofilm formation, but it does not inhibit the Staphylococcus aureus 
growth when it is immobilized in multiwalled carbon nanotubes [38].
AMPs can also cause biofilm matrix disruption. The human liver-derived 
hepcidin 20 peptide can reduce the mass of extracellular matrix and can alter the S. 
epidermidis biofilm architecture by targeting polysaccharide intercellular adhesin 
(PIA). Being endowed with nucleosidase activity, the fish-derived piscidin-3 pep-
tide can degrade P. aeruginosa extracellular DNA by coordinating with Cu2+ through 
its N-terminus [39, 40].
Although several antimicrobial peptides have nowadays been studied for the 
inhibition of biofilm formation, a further aspect needs to be considered. Several 
biofilms have developed defense mechanisms to protect themselves from antimicro-
bial agents. The interaction with EPS is thought to be the principal reason of biofilm 
resistance to AMPs even if the exact mechanism is not well understood. Gram-
negative bacteria, such as P. aeruginosa, can secrete alginate, an anionic extracel-
lular polysaccharide consisting of uronic acid D-mannuronate and C-5 epimer-L 
guluronate. Alginate can interact with cationic AMPs and protect P. aeruginosa 
biofilm from the effect of the antimicrobial peptides [41]. Moreover, the peptide 
sensing system known as aps, first recognized in S. epidermidis, can protect Gram-
positive bacteria from AMP action. This system upregulates the D-alanylation of 
teichoic acid and increases the expression of putative AMP efflux pumps. It was 
demonstrated that Enterococcus faecalis D-alanine deficient mutant is more resistant 
to AMPs than the wild type even if they produce less biofilm [42].
4. Biofilm inhibition by protein targets
Planktonic bacteria can adhere to different cells or tissues starting biofilm 
formation via production of a multitude of proteins, which act at different stages of 
biofilm formation. Some proteins contribute to biofilm accumulation, while others 
are involved into the mediation of primary attachment to surfaces [43, 44]. For this 
reason, the formation and the development of bacterial biofilm can be associated 
with the production of specific proteins, which play essential roles in the bacterial 
biofilm formation and development. Strategies leading to the identification of 
these proteins are fundamental as they could represent interesting targets to inhibit 
biofilm formation, allowing the development of new antibiofilm agents and proce-
dures [45]. In this paragraph, we will focus on some target proteins involved in the 
production of biofilms in different bacteria: the N-acetylneuraminate lyase (NanA) 
in Escherichia coli, the bifunctional enzyme N-acetyl-D-glucosamine-1-phosphate 
acetyltransferase (GlmU) in Mycobacterium smegmatis, and the surface protein G 
(SasG) in S. aureus.
The NanA protein of E. coli is an enzyme able to recognize the sialic acid, a 
molecule essential to a number of critical biological processes, such as cell recogni-
tion, adhesion, and immune system evasion. NanA catalyzes the transformation of 
sialic acid into pyruvate and N-acetyl-D-mannosammine [46, 47], favoring cell-cell 
adhesion. Therefore, NanA plays a fundamental role in the adhesion development 
of host cells a process of great importance in the formation of biofilm. This enzyme 
is then considered an important target for developing molecules able to reduce 
biofilm accumulation. Recently, a relationship between methylation stress in E. coli 
and the reduction of bacterial adhesion properties thus decreasing its ability to form 
biofilm was reported. This phenomenon was associated with a drastic reduction 
in the expression levels of the NanA protein, suggesting a possible role of NanA in 
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biofilm formation and bacteria host interactions. Using a null NanA mutant and 
DANA, a substrate analog acting as competitive inhibitor, it was demonstrated that 
the downregulation of NanA or inhibition of its enzymatic activity affects biofilm 
formation and adhesion properties of E. coli [48, 49].
Another important protein target is GlmU, a bifunctional enzyme with 
acetyltransferase activity involved in the biosynthesis of Uridine diphosphate 
N-acetylglucosamine (UDP-GlcNAc), a key precursor of β-1,6-N-acetyl-D-
glucosamine polysaccharide adhesin required for biofilm formation [50, 51]. GlmU 
is a possible factor involved in biofilm production in M. smegmatis, a nonpathogenic 
bacterium homologous to the pathogenic M. tuberculosis. The response of M. smeg-
matis to alkylating stress is different from E. coli, resulting in an increase in biofilm 
formation possibly due to a very strong defense mechanism. In this contest, GlmU 
has an important role in the process of biofilm production in M. smegmatis, being its 
expression highly upregulated when the bacterium needs to activate defense mecha-
nisms [52]. Experiments with both conditional deletion and overexpressing glmU 
mutants demonstrated that the downregulation of GlmU decreased M. smegmatis 
capabilities to produce biofilm, whereas the overexpression of enzyme increased bio-
film formation. These results were supported by inhibition of GlmU acetyltransfer-
ase activity with two different inhibitors, suggesting the involvement of this enzyme 
in the M. smegmatis defense mechanisms. Focusing on the inhibition of GlmU might 
then be an efficient method to disable the bacterium defense mechanism.
S. aureus is a common pathogen responsible for nosocomial and community 
infections being able to colonize the squamous epithelium of the anterior nares. 
One of the adhesins likely to be responsible for this ability is the S. aureus surface 
protein G (SasG), which promotes cellular aggregation leading to biofilm forma-
tion [53, 54]. SasG comprises an N-terminal A domain and repeated B domains 
with only the B domain required for the accumulation of biofilm. Expression of 
SasG does not increase the adherence of bacteria, and it is not involved in primary 
attachment but plays a role in the accumulation phase of biofilm formation [55]. 
For different aspects and playing different roles, NanA, GlmU, and SasG may all 
represent interesting targets to address the inhibition of biofilm production.
5. Conclusions
Currently, biofilm infections constitute a serious medical problem, and their 
treatment is far from being satisfactory. Biofilm formation inhibitors have several 
potential therapeutic applications as coatings in medical devices or in the prophy-
laxis of implanted surgery. In this respect, the identification of new strategies to 
counteract biofilm formation is a broad subject of study. The antibiofilm activity of 
many molecules such as proteins, peptides, and small organic molecules is currently 
under investigation. Each of these molecules is endowed with specific character-
istics and can exert its ability to inhibit bacterial biofilm formation with different 
mechanisms. Antibiofilm agents are able to act both at the initial stages of biofilm 
formation, such as bacterial adhesion to the host surface, and on preformed biofilm, 
leading to the disruption of the EPS architecture. Many small organic molecules 
are able to interfere with the bacterial QS system, but their lack of activity in in 
vivo models and the high toxicity make these molecules of limited use in clinical 
applications.
As antimicrobial peptides show a broad spectrum of action, exploiting different 
activities including antibiofilm capabilities, these molecules might be considered 
as new promising factors to impair biofilm formation that exploit different mecha-
nisms to hamper biofilms at different stages.
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The administration of a single antibiotic is often not enough to eradicate bacte-
rial invasions, and a high concentration of the antibiotic can be extremely toxic. 
A possible solution might be the coadministration of antibiotics with antibiofilm 
peptides that allow the use of low antibiotic concentrations. This strategy can be 
tuned to affect biofilms without killing bacteria, thus avoiding the emergence of 
drug-resistant populations through synergy with existing antibiotics.
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